Ros M Malyz

Dr. Ros M Malyz

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RMRos M Malyz
Ros M Malyz
JKJeremy Keirsey
Jeremy Keirsey
SKSandra C Kim
Sandra C Kim
Amy MackosAmy Mackos
Amy Mackos
RGRaad Z Gharaibeh
Raad Z Gharaibeh
Michael BaileyMichael Bailey
Michael Bailey
Stressor-exposure has been shown to exacerbate inflammation and change the composition of the gastrointestinal microbiota; however stressor-induced effects on microbiota-derived metabolites and their receptors are unknown. Thus, bacterial-produced short chain fatty acids (SCFAs), as well as microbial community composition, were assessed in the colons of mice exposed to stress during infection with Citrobacter rodentium. Mice were exposed to overnight restraint on 7 consecutive nights, or left undisturbed as a control. After the first exposure of restraint, mice were orally challenged with C. rodentium or with vehicle. Microbial community composition was assessed using 16S rRNA gene sequencing and SCFA levels measured using gas chromatography-mass spectrometry (GC-MS). Pathogen levels and colonic inflammation were also assessed 6 days post-infection. Results demonstrated that the microbial community structure and SCFA production were significantly affected by both stressor exposure and C. rodentium-infection. Exposure to prolonged restraint in the absence of infection significantly reduced SCFAs (acetic acid, butyric acid, and propionic acid). Multiple bacterial taxa were affected by stressor exposure, with the relative abundance of Lactobacillus being significantly reduced and directly correlated with propionic acid. Lactobacillus abundances were inversely correlated with colonic inflammation, supporting the contention that Lactobacillus helps to regulate mucosal inflammatory responses. Our data indicates that restraint stressor can have significant effects on pathogen-induced colonic inflammation and suggest that stressor-induced changes in the microbiota, microbial-produced SCFAs and their receptors may be involved.

27 April 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
SSShilpa Sridhar
Shilpa Sridhar
RMRos M Malyz
Ros M Malyz
BBBrendan Boyle
Brendan Boyle
SKSandra C Kim
Sandra C Kim
Anti-tumor necrosis factor (anti-TNF) therapies are effective treatments for inflammatory bowel diseases (IBD). However, infections, psoriasis, and eczema are potential manifestations. Descriptions of these are limited. Our aim was to characterize these skin manifestations in children with IBD on anti-TNF therapy. Our study is a retrospective review of IBD patients ranging in age from 6 to 18 years who were treated with anti-TNFs from 2010–2015. Data collected included demographics, clinical information, anti-TNF therapy used, and whether patients developed skin manifestations and their type of complication, clinical interventions, and outcomes. Of the 409 patients analyzed, 47 (11.4%) developed dermatologic manifestations (39 CD, 8 UC/IC). Among these 47 patients, there were 72 manifestations of infections (28/72; 38.9%), psoriasis (33/72; 45.8%), and eczema (10/72; 13.9%). There was no significant difference between patients with CD and UC/IC in the type of manifestation. Children on infliximab experienced an increased risk of psoriasis than those on adalimumab (P = 0.05). A greater percentage of female patients developed a skin manifestation (28/47; 60%). The majority of patients with a skin manifestation were able to continue the current anti-TNF regimen. Amongst the patients that developed psoriasis, 60% did not require change in anti-TNF therapy. This is the largest study analyzing anti-TNF related skin manifestations in a pediatric IBD cohort. Psoriasiform lesions were the most prevalent dermatological manifestation, and females experienced more reactions than males. Most patients were able to continue their anti-TNF therapy. However, if a change was required, it was most likely among those who developed psoriasis and required either a dose or interval change, different anti-TNF medication, or a medication class change.

25 May 2021 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
GMGrant A Morris
Grant A Morris
MMMegan McNicol
Megan McNicol
BBBrendan Boyle
Brendan Boyle
ADAmy Donegan
Amy Donegan
JDJennifer Dotson
Jennifer Dotson
RMRos M Malyz
Ros M Malyz
Background: Tumor necrosis factor-alpha inhibitors (anti-TNFs) are a primary treatment for inflammatory bowel disease. Pharmaceutical expenditures and usage of specialty drugs are increasing. In the United States, biosimilars continue to be underutilized, despite opportunities for health care cost savings. Through quality improvement (QI) methodology, we aimed to increase biosimilar utilization among eligible patients initiating intravenous (IV) anti-TNF therapy and describe patient outcomes and associated cost savings. Methods: Beginning in July 2019, all patients initiating IV anti-TNF therapy were identified and tracked. Using the Institute of Healthcare Improvement Plan-Do-Study-Act cycle, a four-stage problem-solving model used for carrying out change, we trialed interventions to increase biosimilar utilization, including provider, staff, and family education, and utilization of a clinical pharmacist and insurance specialist. Statistical process control charts were used to show improvement over time. Patients’ clinical outcome and cost savings were reviewed. Results: Using QI methodology, we increased biosimilar utilization from a baseline of 1% in June 2019 to 96% by February 2021, with sustained improvement. The originator (infliximab) was the insurance company’s preferred product for 20 patients (20%). Patient outcomes (IV anti-TNF levels, absence of antidrug antibodies, and physician global assessment) between biosimilars and originators were similar. Estimated cost savings over the project duration were nearly $381,000 (average sales price) and $651,000 (wholesale acquisition cost). Conclusions: Through QI methodology, we increased biosimilar utilization from 1% to 96% with sustained improvement, without compromising patient outcomes or safety. Estimated cost savings were substantial. Similar methodology could be implemented at other institutions to increase biosimilar utilization and potentially decrease health care costs.

1 September 2021 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
HMHilary Michel
Hilary Michel
BBBrendan Boyle
Brendan Boyle
JDJennie G David
Jennie G David
ADAmy Donegan
Amy Donegan
BDBarb Drobnic
Barb Drobnic
JDJennifer L Dotson
Jennifer L Dotson
Care for patients with inflammatory bowel disease (IBD) can be complex and costly. Care delivery models to address these challenges and improve care quality are essential. The patient-centered medical home (PCMH), which was developed in the primary care setting, has recently been applied successfully to the adult IBD population. Following the tenets of the PCMH, this specialty medical home (SMH) emphasizes team-based care that is accessible, comprehensive, patient/family-centered, coordinated, compassionate, and continuous and has demonstrated improved patient outcomes. Children and young adults with IBD have equally complex care needs, with additional challenges not faced by the adult population such as growth, physical and psychosocial development, and transition of care from pediatric to adult providers. Thus, we advocate that the components of the PCMH are equally—if not more—important in caring for the pediatric patient population. In this article, we review what is known about the application of the PCMH model in adult IBD care, describe care delivery within the Center for Pediatric and Adolescent IBD at Nationwide Children’s Hospital as an example of a pediatric IBD medical home, and propose a research agenda to further the development and dissemination of comprehensive care delivery for children and adolescents with IBD.

7 July 2021 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
SSSalman S. Salman
Salman S. Salman
KWKent C. Williams
Kent C. Williams
PMPedro Marte‐Ortiz
Pedro Marte‐Ortiz
WRWolfgang Rumpf
Wolfgang Rumpf
LMLauren Mashburn‐Warren
Lauren Mashburn‐Warren
RMRos M Malyz
Ros M Malyz

23 February 2023 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
RMRos M Malyz
Ros M Malyz
MMMadeline G. BS McClinchie
Madeline G. BS McClinchie
BBBrendan M. Boyle
Brendan M. Boyle
MMMegan PharmD McNicol
Megan PharmD McNicol
GMGrant A. Morris
Grant A. Morris
SKSandra C. Kim
Sandra C. Kim